問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Infectious Disease

Division of Thoracic Medicine

Division of Others-

Kaohsiung Municipal Ta-Tung Hospital

Division of Infectious Disease

更新時間：2023-11-02

林尚儀Lin, Shang-Yi
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

  • amoe616@kmu.edu.tw

Recruiting Trial

22Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林尚儀

List

41Cases

2025-09-01 - 2029-12-31

Not yet recruiting
A Phase 2, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V540A in Healthy Females 16 to 26 Years of Age

  • Condition/Disease

    Healthy

  • Test Drug

    注射劑 注射劑

Participate Sites
6Sites

Recruiting6Sites

2025-03-31 - 2028-06-30

Active
A retrospective, observational post-marketing study evaluating the efficacy and safety of intravenously administered polymyxin B and colistin methanesulfonate in treating patients with carbapenem-resistant, Gram-negative bacterial infections.

  • Condition/Disease

    1. Clinical response rate of the polymyxin B group assessed by infection site and infectious pathogen at TOC (End of Treatment (EOT) + 7 days). 2. Clinical response rate of the two treatment groups at TOC. 3. Microbiological response rate of the polymyxin B group assessed by infection site and infectious pathogen at TOC. 4. Microbiological response rate of the two treatment groups at TOC. 5. All-cause mortality rate of the two treatment groups at day 28. 6. Infection-related mortality rate of the two treatment groups at day 28.

  • Test Drug

    POLYMYXIN B SULFATE

Participate Sites
13Sites

Recruiting13Sites

2025-04-01 - 2027-11-30

Not yet recruiting
A randomized, double-blind, placebo-controlled phase 3 trial is investigating the use of VE303 for the prevention of recurrent Clostridium difficile infection.

  • Condition/Disease

    Double-blind, placebo-controlled trial: Proportion of participants with laboratory-confirmed CDI recurrence by week 8

  • Test Drug

    VE303

Participate Sites
3Sites

Recruiting3Sites

2018-08-01 - 2023-01-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

2018-05-01 - 2023-05-17

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting6Sites

2023-07-03 - 2026-12-31

Phase II/III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-12-15 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting5Sites

Recruiting4Sites

2025-12-01 - 2029-01-04

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

2025-03-31 - 2027-07-31

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2022-10-27 - 2030-01-21

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB